Pfizer Inc. CEO Albert Bourla said mixing and matching covid-19 vaccines and boosters could work and provide more flexibility in vaccine administration.
Preliminary results of a study by the National Institutes of Health (NIHfrom the United States found that mixing and matching vaccines produces as many or more antibodies as using the same vaccine as a booster.
Bourla said in an interview on “Balance of Power with David Westin”From Bloomberg TV that the study was very reliable even though it only involved a modest number of patients.
The Food and Drug Administration (FDAis prepared to authorize recipients to receive a booster shot from a different manufacturer. The agency is still considering how broad such authorization would be, and it is unclear when a decision could be announced.
Pfizer and its partner BioNTech SE received approval from the FDA for your booster shot last month. The agency is expected to also approve the Moderna Inc. vaccine boosters and Johnson & Johnson this week after they received endorsement from a panel of FDA scientific advisers.
The advisers did not make a recommendation on the vaccine mix, however, some indicated that they were open to it.
Bourla said the Pfizer vaccine in children ages 5 to 11 was likely to be licensed by the end of the month, according to the advisory panel meeting scheduled by the FDA to review the data on October 26.
If that vaccine, which is one-third the dose now approved for adults, gets emergency clearance, Bourla noted that Pfizer could “administer almost immediately”.
.
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
